Consensus Viking Therapeutics, Inc.

Equities

VKTX

US92686J1060

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
76.97 ^USD	+1.60%		+3.58%	+313.59%

03/05	Wall St set to open sharply higher on soft jobs data	RE
03/05	Amgen shares jump after teasing weight-loss drug data, rivals slip	RE

Evolution of the average Target Price on Viking Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c871b49f230b7ad9cf98d246aa7a8d.nZs1e6pY69YwZyN7tpKM6ef04MOn--ixs7tUDgzux4c._uNtP5wAjIReJUADjvDosYSWrJLziY3ryuMTaHaar9fn6Awvwz_G5GcRGw~d97e10625257d7fce36421d626f3ee0a

Analyst Recommendations on Viking Therapeutics, Inc.

Viking Therapeutics Insider Sold Shares Worth $22,136,474, According to a Recent SEC Filing	03/05	MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $138 From $116, Maintains Outperform Rating	27/03	MT
Stifel Adjusts Viking Therapeutics Price Target to $95 From $80, Maintains Buy Rating	26/03	MT
BTIG Raises Price Target on Viking Therapeutics to $100 From $86, Keeps Buy Rating	15/03	MT
Jefferies Starts Viking Therapeutics With Buy Rating, $110 Price Target	07/03	MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $116 From $46, Maintains Outperform Rating	28/02	MT
HC Wainwright Raises Price Target on Viking Therapeutics to $90 From $33, Keeps Buy Rating	27/02	MT
Stifel Adjusts Price Target on Viking Therapeutics to $35 From $30, Maintains Buy Rating	14/02	MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $46 From $40, Maintains Outperform Rating	08/02	MT
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	08/23/08	DJ
Raymond James Adjusts Viking Therapeutics Price Target to $37 From $35, Maintains Outperform Rating	17/23/17	MT
Stifel Adjusts Viking Therapeutics' Price Target to $30 From $25, Keeps Buy Rating	16/23/16	MT
BTIG Adjusts Viking Therapeutics' Price Target to $36 From $31, Keeps Buy Rating	16/23/16	MT
Roth MKM Adjusts Price Target on Viking Therapeutics to $24 From $19, Maintains Buy Rating	03/23/03	MT
HC Wainwright Adjusts Price Target on Viking Therapeutics to $33 From $21, Maintains Buy Rating	27/23/27	MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $35 From $30, Maintains Outperform Rating	25/23/25	MT
BTIG Research Adjusts Viking Therapeutics Price Target to $31 From $20, Maintains Buy Rating	29/23/29	MT
Raymond James Adjusts Viking Therapeutics Price Target to $35 From $12, Maintains Outperform Rating	29/23/29	MT
Stifel Nicolaus Adjusts Viking Therapeutics Price Target to $25 From $22, Maintains Buy Rating	28/23/28	MT
Stifel Initiates Viking Therapeutics at Buy With $22 Price Target	17/23/17	MT
Raymond James Adjusts Price Target on Viking Therapeutics to $12 From $11, Maintains Outperform Rating	09/23/09	MT
Oppenheimer Adjusts Viking Therapeutics' Price Target to $17 From $15, Maintains Outperform Rating	09/23/09	MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $15 From $13, Maintains Outperform Rating	30/23/30	MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $13 From $10, Maintains Outperform Rating	20/22/20	MT
Maxim Group Adjusts Viking Therapeutics Price Target to $15 From $10, Maintains Buy Rating	20/22/20	MT